In Japan, colorectal cancer has the highest mortality rate among females and the third highest among males, and the number of deaths has tripled in 1 years.It is known that most colorectal cancers develop due to mutations in multiple genes, and the tumor suppressor gene p3, which is called the "guardian of the genome," is known as a typical causative gene.
This time, a research group of Kyoto University et al. Revealed that suppression of a protein called naldilysin activates the function of p53 and suppresses the onset and progression of colorectal cancer.Nardilysin controls various biological phenomena such as thermoregulation and insulin secretion, and has been shown to play an important role in gastric cancer and hepatocellular carcinoma. It was previously unknown if he was involved.
In this study, we investigated the case where naldilysin was suppressed and the case where it was increased using colorectal cancer model mice.As a result, it was found that suppressing the progression of colorectal cancer in the intestinal epithelium suppresses the progression of colorectal cancer, and conversely, increasing the amount of naldilysin promotes the progression of colorectal cancer.Furthermore, examination of mouse intestinal polyps revealed that p53 expression decreased with increasing naldilysin. p53 is a "genome guardian deity" that has the function of repairing DNA damage that causes canceration of cells and the function of inducing cell death of cancerous cells.In a study using colorectal cancer cells, it was found that suppressing the expression of naldilysin stabilizes the expression of p53, and as a result, it was suggested that the onset and progression of colorectal cancer were suppressed.
Based on this result, which revealed for the first time that naldilysin is a regulator of p53, it is expected to develop a new therapeutic method targeting naldilysin.
Paper information:[JCI Insight] Nardilysin controls intestinal tumorigenesis through HDAC1 / p53–dependent transcriptional regulation
